takeover

Liberty Media, the conglomerate controlled by John Malone, made a $1 billion bid Thursday to buy Barnes & Noble. The bricks-and-mortar bookstore business is declining everywhere, so for Malone's gamble is to pay off, the Nook will have to gain some ground against Apple's iPad and Amazon's Kindle.

Citigroup has foreclosed on U.K.-based record label EMI Group, taking it back from private-equity firm Terra Firma, which bought EMI from Citigroup for a whopping $4.7 billion in 2007.

The European Commission on Wednesday approved Intel's $7.68 billion acquisition of security-software company McAfee. Regulators had been concerned that the deal would exclude competing software from working with Intel processors, but Intel agreed to maintain interoperability.

Companies such as Duke Energy and DuPont are off and running with megamergers early this year. Even Playboy is among the dealers. And market pros say the trend is far from over. Why are so many U.S. companies tying the knot? Fast growth is hard to come by in any other strategy.

The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.

Hedge fund manger Bill Ackman says he will finance a takeover bid for rival bookseller Barnes & Noble at $16 a share -- a 20.5% premium over Friday's closing price. Faced with increased competition, B&N has seen sales plunge in recent quarters.

Genzyme, which makes drugs to treat leukemia and multiple sclerosis, has rejected a hostile takeover bid from French drugmaker Sanofi-Aventis. The offer "dramatically undervalues" Genzyme, the company said Friday, putting its value about 30% higher.

AOL is reported to be collaborating with private equity firms to explore a possible Yahoo takeover attempt. In theory, an AOL-Yahoo deal would position the merged company to compete for online advertising dollars more effectively.

Food giant Sara Lee saw its shares surge over 18% in premarket trading Monday after the New York Post reported the company turned down a $12 billion buyout offer from private-equity company KKR & Co.), citing unnamed sources.

Sanofi-Aventis CEO Chris Viehbacher said Wednesday that he believes his French pharmaceutical company will eventually buy U.S. biotech company Genzyme at a reasonable price. However, he expects it will take some time to agree on a deal, and he won't rush into anything.